Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2012

Open Access 01-12-2012 | Research

LMP1 and LMP2A are potential prognostic markers of extranodal NK/T-cell lymphoma, nasal type (ENKTL)

Authors: Yuan Mao, Da-Wei Zhang, Huijun Zhu, Hong Lin, Lin Xiong, Qing Cao, Ying Liu, Qing-Dong Li, Jia-Ren Xu, Lin-Feng Xu, Ren-Jie Chen

Published in: Diagnostic Pathology | Issue 1/2012

Login to get access

Abstract

Background

Latent membrane protein (LMP) 1 and LMP2A encoded by Epstein-Barr virus (EBV) are associated with the development of malignancies, but their expression in extranodal NK/T-cell lymphoma, nasal type (ENKTL) and the relationship with clinical characteristics of this disease remain poorly understood. In the present study, we examined the expression of LMP1 and LMP2A in ENKTL, and investigated the correlations between LMP1 and LMP2A expression with clinicopathological characteristics of ENKTL patients.

Methods

Paraffin sections of surgically removed samples from 16 ENKTL patients were analyzed by immunohistochemistry and the related clinicopathological data were collected and analyzed.

Results

Elevated expression (immunohistochemistry score ≥ 4) of LMP1 and LMP2A was detected in the tumor cells of ENKTL. High LMP1 expression was associated with positive B symptoms (p = 0.012), while high LMP2A expression was related to gender (p = 0.029). The expression of both LMP1 and LMP2A showed significant correlations with patients’ overall survival (p = 0.049, p = 0.036).

Conclusion

LMP1 and LMP2A may be prognostic indicators of survival in patients with ENKTL.
Appendix
Available only for authorised users
Literature
1.
Jaffe ES, Harris NL, Stein H, Vardiman JW: WHO classification of tumours. Volume 3: pathology and genetics of tumours of haematopoietic and lymphoid tissue. 2001, Lyon: IARC Press
2.
Pongpruttipan T, Kummalue T, Bedavanija A, Khuhapinant A, Ohshima K, Arakawa F, Niino D, Sukpanichnant S: Aberrant antigenic expression in extranodal NK/T-cell lymphoma: a multi-parameter study from Thailand. Diagn Pathol. 2011, 6: 79-10.1186/1746-1596-6-79.PubMedCentralCrossRefPubMed
3.
Cao W, Liu Y, Zhang H, Wang S, Zhang L, Zhang L, Sun B: Expression of LMP-1 and cyclin D1 protein is correlated with an unfavorable prognosis in nasal type NK/T cell lymphoma. Mol Med Report. 2008, 1: 363-368.
4.
Suzuki R, Suzumiya J, Yamaguchi M, Nakamura S, Kameoka J, Kojima H, Abe M, Kinoshita T, Yoshino T, Iwatsuki K, Kagami Y, Tsuzuki T, Kurokawa M, Ito K, Kawa K, Oshimi K, NK-cell Tumor Study Group: Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol. 2010, 21: 1032-1040. 10.1093/annonc/mdp418.CrossRefPubMed
5.
Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, Lee SW, Kim JS, Cho J, Lee GW, Kang KM, Eom HS, Pyo HR, Ahn YC, Ko YH, Kim WS: Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: consortium for improving survival of lymphoma study. J Clin Oncol. 2009, 27: 6027-6032. 10.1200/JCO.2009.23.8592.CrossRefPubMed
6.
Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, Wasada I, Kinoshita T, Ohshima K, Matsuno Y, Terauchi T, Nawano S, Ishikura S, Kagami Y, Hotta T, Oshimi K: Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan clinical oncology group study JCOG0211. J Clin Oncol. 2009, 27: 5594-5600. 10.1200/JCO.2009.23.8295.CrossRefPubMed
7.
Pagano L, Gallamini A, Trapè G, Fianchi L, Mattei D, Todeschini G, Spadea A, Cinieri S, Lannitto E, Martelli M, Nosari A, Bona ED, Tosti ME, Petti MC, Falcucci P, Montanaro M, Pulsoni A, Larocca LM, Leone G, Intergruppo Italiano Linfomi: NK/T-cell lymphomas ‘nasal type’: an Italian multicentric retrospective survey. Ann Oncol. 2006, 17: 794-800. 10.1093/annonc/mdl015.CrossRefPubMed
8.
Takahashi E, Ohshima K, Kimura H, Hara K, Suzuki R, Kawa K, Eimoto T, Nakamura S, NK-cell Tumor Study Group: Clinicopathological analysis of the age-related differences in patients with Epstein–Barr virus (EBV)-associated extranasal natural killer (NK)/T-cell lymphoma with reference to the relationship with aggressive NK cell leukaemia and chronic active EBV infection-associated lymphoproliferative disorders. Histopathology. 2011, 59: 660-671. 10.1111/j.1365-2559.2011.03976.x.CrossRefPubMed
9.
Carbone A, Gloghini A, Dotti G: EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist. 2008, 13: 577-585. 10.1634/theoncologist.2008-0036.CrossRefPubMed
10.
Cohen JI, Bollard CM, Khanna R, Pittaluga S: Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas. Leuk Lymphoma. 2008, 1: 27-34.CrossRef
11.
Kohrt H, Advani R: Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment. Leuk Lymphoma. 2009, 50: 1773-1784. 10.3109/10428190903186502.CrossRefPubMed
12.
Yang QX, Pei XJ, Tian XY, Li Y, Li Z: Secondary cutaneous Epstein-Barr virus-associated diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma: a case report and review of literature. Diagn Pathol. 2012, 7: 7-10.1186/1746-1596-7-7.PubMedCentralCrossRefPubMed
13.
Kieff ED, Rickinson AB, et al.: Epstein-Barr virus and its replication. Fields virology, vol 2. Edited by: Knipe DM. 2007, Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2603-2654. 5
14.
Shair KH, Bendt KM, Edwards RH, Bedford EC, Nielsen JN, Raab-Traub N: EBV latent membrane protein 1 activates Akt, NFkappaB, and Stat3 in B cell lymphomas. PLoS Pathog. 2007, 3: e166-10.1371/journal.ppat.0030166.PubMedCentralCrossRefPubMed
15.
Vrzalikova K, Vockerodt M, Leonard S, Bell A, Wei W, Schrader A, Wright KL, Kube D, Rowe M, Woodman CB, Murray PG: Down-regulation of BLIMP1α by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas. Blood. 2011, 117: 5907-5917. 10.1182/blood-2010-09-307710.PubMedCentralCrossRefPubMed
16.
Chen F, Liu C, Lindvall C, Xu D, Ernberg I: Epstein-Barr virus latent membrane 2A (LMP2A) down-regulates telomerase reverse transcriptase(hTERT) in epithelial cell lines. Int J Cancer. 2005, 113: 284-289. 10.1002/ijc.20594.CrossRefPubMed
17.
Pang MF, Lin KW, Peh SC: The signaling pathways of Epstein-Barr virus-encoded latent membrane protein 2A (LMP2A) inlatency and cancer. Cell Mol Biol Lett. 2009, 14: 222-247. 10.2478/s11658-008-0045-2.CrossRefPubMed
18.
Mancao C, Hammerschmidt W: Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood. 2007, 110: 3715-3721. 10.1182/blood-2007-05-090142.PubMedCentralCrossRefPubMed
19.
Bieging KT, Swanson-Mungerson M, Amick AC, Longnecker R: Epstein-Barr virus in Burkitt’s lymphoma: a role for latent membrane protein 2A. Cell Cycle. 2010, 9: 901-908. 10.4161/cc.9.5.10840.PubMedCentralCrossRefPubMed
20.
Portis T, Dyck P, Longnecker R: Epstein-Barr virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in reed-Sternberg cells of Hodgkin lymphoma. Blood. 2003, 102: 4166-4178. 10.1182/blood-2003-04-1018.CrossRefPubMed
21.
Liang X, Graham DK: Natural killer cell neoplasms. Cancer. 2008, 112: 1425-1436. 10.1002/cncr.23316.CrossRefPubMed
22.
Friedrich M, Villena-Heinsen C, Reitnauer K, Schmidt W, Tilgen W, Reichrath J: Malignancies of the uterine corpus and immunoreactivity score of the DNA “mismatch-repair” enzyme human Mut-S-homologon-2. J Histochem Cytochem. 1999, 47: 113-118. 10.1177/002215549904700112.CrossRefPubMed
23.
Mao Y, Zhang DW, Wen J, Cao Q, Chen RJ, Zhu J, Feng ZQ: A novel LMP1 antibody synergizes with mitomycin C to inhibit nasopharyngeal carcinoma growth in vivo through inducing apoptosis and downregulating vascular endothelial growth factor. Int J Mol Sci. 2012, 13: 2208-2218. 10.3390/ijms13022208.PubMedCentralCrossRefPubMed
24.
Ho CH, Chen CL, Li WY, Chen CJ: Decoy receptor 3, upregulated by Epstein-Barr virus latent membrane protein 1, enhances nasopharyngeal carcinoma cell migration and invasion. Carcinogenesis. 2009, 30: 1443-1451. 10.1093/carcin/bgp135.CrossRefPubMed
25.
Chen R, Zhang D, Mao Y, Zhu J, Ming H, Wen J, Ma J, Cao Q, Lin H, Tang Q, Liang J, Feng Z: A human Fab-based immunoconjugate specific for the LMP1 extracellular domain inhibits nasopharyngeal carcinoma growth in vitro and in vivo. Mol Cancer Ther. 2012, 11: 594-603. 10.1158/1535-7163.MCT-11-0725.CrossRefPubMed
26.
Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G, Khalil M, Wu MF, Huls MH, Chang CC, Gresik MV, Gee AP, Brenner MK, Rooney CM, Heslop HE: Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007, 110: 2838-2845. 10.1182/blood-2007-05-091280.PubMedCentralCrossRefPubMed
27.
Dargart JL, Fish K, Gordon LI, Longnecker R, Cen O: Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A. Antiviral Res. 2012, 95: 49-56. 10.1016/j.antiviral.2012.05.003.PubMedCentralCrossRefPubMed
28.
Fox CP, Haigh TA, Taylor GS, Long HM, Lee SP, Shannon-Lowe C, O’Connor S, Bollard CM, Iqbal J, Chan WC, Rickinson AB, Bell AI, Rowe M: A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood. 2010, 116: 3695-3704. 10.1182/blood-2010-06-292268.PubMedCentralCrossRefPubMed
29.
Du ZM, Kou CW, Wang HY, Huang MY, Liao DZ, Hu CF, Chen J, Yan LX, Hu LF, Ernberg I, Zeng YX, Shao JY: Clinical significance of elevated spleen tyrosine kinase expression in nasopharyngeal carcinoma. Head Neck. 2012, 34: 1456-1464. 10.1002/hed.21953.CrossRefPubMed
Metadata
Title
LMP1 and LMP2A are potential prognostic markers of extranodal NK/T-cell lymphoma, nasal type (ENKTL)
Authors
Yuan Mao
Da-Wei Zhang
Huijun Zhu
Hong Lin
Lin Xiong
Qing Cao
Ying Liu
Qing-Dong Li
Jia-Ren Xu
Lin-Feng Xu
Ren-Jie Chen
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2012
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-7-178

Other articles of this Issue 1/2012

Diagnostic Pathology 1/2012 Go to the issue

Case Report

Pathological femoral fractures due to osteomalacia associated with adefovir dipivoxil treatment for hepatitis B: a case report

Research

Lower cyclooxygenase-2 expression is associated with recurrence of solitary non-muscle invasive bladder carcinoma

Research

Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors

Research

Diagnostic approach to interstitial pneumonias in a single centre: report on 88 cases

Research

Effect of image compression and scaling on automated scoring of immunohistochemical stainings and segmentation of tumor epithelium

Case Report

Colloid cyst of the third ventricle, hypothalamus, and heart: a dangerous link for sudden death